Treatment Macular Degeneration and Aflibercept

Search results

- Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
  Zacks via Yahoo Finance· 1 week ago
  In August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with...
- These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
  TipRanks via Yahoo Finance· 2 days ago
  Risk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
- Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for...
  WKRN Nashville· 2 weeks ago
  EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the
- Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
  Zacks· 2 weeks ago
  The Zacks Consensus Estimate for REGN’s first-quarter revenues is pegged at $3.2 billion, while the same for earnings is pinned at $10.20 per share. A significant chunk of Regeneron’s revenues ...
- Small Business - The Andalusia Star-News | The Andalusia Star-News
  The Andalusia Star-News· 1 week ago
  First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first